
This story was made possible through support from TEDCO, the Maryland Technology Development Corporation, which enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at tedcomd.com. All stories are independently reported, with no partner review.
Baltimore biotech startup SereNeuro Therapeutics announced today the close of a pre-seed funding round.
The Johns Hopkins University spinout is developing a non-opioid therapy for osteoarthritis joint pain. The company declined to share an exact amount for the round, but said it has already used some of the funding to hire additional staff.
That includes bringing on Laura Richman as part-time chief science officer. Richman, who also acts as chief development officer at Boston-based Affinia Therapeutics, has a solid track record in the region: She previously served as senior vice president of Rockville-area Arcellx during its early stages. In February, Arcellx was acquired by pharmaceutical giant Gilead Sciences in an $8 billion deal.
SereNeuro’s lead therapy candidate injects pain-sensing neurons directly into affected joints.
“We’re really thrilled to have Laura joining,” SereNeuro CEO Dan Saragnese told Technical.ly, “to lead our early development and translational science.”
SereNeuro also recently secured its first Small Business Innovation Research (SBIR) grant from the National Institutes of Health, Saragnese said, in the amount of $318,000. The program had been stalled after Congress allowed it to lapse for six months, before reauthorizing the program in April.
At the beginning of this year, SereNeuro earned a spot on Technical.ly’s RealLIST Startups feature. At the time, the company told Technical.ly it had raised $898,765, including support from the Maryland Stem Cell Research Fund.
Founded in 2024, SereNeuro takes what Sarganese describes as a counterintuitive approach to pain management.
Its lead cell therapy candidate, called SN101, injects pain-sensing neurons directly into affected joints. Those neurons act as a “pain sponge,” soaking up the pain and inflammatory signals causing the discomfort. Unlike opioids, which trigger pleasure sensors across the whole body and carry a high risk of addiction, SN101 operates strictly at the site of the pain.
The company has tested its therapy in primates and gathered data from joint fluid samples of human osteoarthritis patients. Now, the team is gearing up for a November meeting with the FDA to initiate the formal development process.
“We’re really squeezing the juice of that data,” Saragnese said, “before going to the FDA.”